Keryx Biopharma - KERX

Aeiou ha scritto:
Ciao Acqua+, il link non mi si apre, cosa dice? Buone nuove? In ogni caso buona serata a te! :-)
Clicca per allargare...

a me il link si apre tuttora

NOTICE OF 2009 ANNUAL MEETING OF STOCKHOLDERS

The 2009 Annual Meeting of Stockholders of Keryx Biopharmaceuticals, Inc. will be held at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016, on Tuesday, June 16, 2009, at 10:00 a.m., local time. At the meeting, stockholders will consider and act on the following items:
​
1.The election of four directors to our Board of Directors for a term of one year;
2.The ratification of the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2009; and
3.The transaction of any other business that may properly come before the 2009 Annual Meeting or any adjournment of the 2009 Annual Meeting.

Only those stockholders of record as of the close of business on April 20, 2009, are entitled to vote at the 2009 Annual Meeting or any postponements or adjournments thereof.
A complete list of stockholders entitled to vote at the 2009 Annual Meeting will be available for your inspection beginning June 5, 2009, at our offices located at 750 Lexington Avenue, New York, New York 10022, between the hours of 10:00 a.m. and 5:00 p.m., local time, each business day.​
 
magolibero ha scritto:
a me il link si apre tuttora

NOTICE OF 2009 ANNUAL MEETING OF STOCKHOLDERS

The 2009 Annual Meeting of Stockholders of Keryx Biopharmaceuticals, Inc. will be held at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016, on Tuesday, June 16, 2009, at 10:00 a.m., local time. At the meeting, stockholders will consider and act on the following items:
​
1.The election of four directors to our Board of Directors for a term of one year;
2.The ratification of the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2009; and
3.The transaction of any other business that may properly come before the 2009 Annual Meeting or any adjournment of the 2009 Annual Meeting.

Only those stockholders of record as of the close of business on April 20, 2009, are entitled to vote at the 2009 Annual Meeting or any postponements or adjournments thereof.
A complete list of stockholders entitled to vote at the 2009 Annual Meeting will be available for your inspection beginning June 5, 2009, at our offices located at 750 Lexington Avenue, New York, New York 10022, between the hours of 10:00 a.m. and 5:00 p.m., local time, each business day.​
Clicca per allargare...

Grazie Mago! :) Da quel che posso capire la UHY LLP si occupa di brevetti, certificazioni, etc. http://www.uhyllp-us.com/uhyllp/default.aspx
 
:-?

ma cosa rappresentano 100pezzi100 che in AH con il loro prezzo le stanno facendo fare quasi il 100% ?
..
..
1241471789keryx.jpg



la butto lì ? :specchio:

[X]
+
[Y]
+
[Z]
=

potrà essere che domani Merc 6Maggio, Aeterna Zentaris (Nasdaq : AEZS) e Keryx uniscono loro "energie" con "supporto" di partner asiatico ?


========================================

[X]

magolibero ha scritto:
http://investors.keryx.com/phoenix.z...hCUkw9MQ%3d%3d

NOTICE OF 2009 ANNUAL MEETING OF STOCKHOLDERS

The 2009 Annual Meeting of Stockholders of Keryx Biopharmaceuticals, Inc. will be held at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016, on Tuesday, June 16, 2009, at 10:00 a.m., local time. At the meeting, stockholders will consider and act on the following items:​

1.The election of four directors to our Board of Directors for a term of one year;
2.The ratification of the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2009; and
3.The transaction of any other business that may properly come before the 2009 Annual Meeting or any adjournment of the 2009 Annual Meeting.
Clicca per allargare...


========================================

[Y]

Keryx del perifosine (KRX-404) possiede i diritti per il NordAmerica
Quelli per il resto del mondo sono di Aeterna Zentaris , e in particolare per l'Asia é alla ricerca di un partner

http://www.aezsinc.com/en/page.php?p=31&prod=3

Development plan

Æterna Zentaris Program



  • Ongoing randomized, double-blind, placebo-controlled Phase 2 trial to assess the efficacy of daily oral perifosine when combined to radiotherapy in the treatment of patients with non small-cell lung cancer.
Keryx Program



  • Monotherapy Phase 1/2 trial in NSCLC
  • Phase 1 trials with Gemcitabine, Paclitaxel and Docetaxel (multiple cancers)
  • Phase 2 trials with Herceptin® and endocrine therapy for breast cancer
  • Phase 2 trials all comers (monotherapy), sarcoma (monotherapy) and in combination with Gleevec®
  • Phase 2 trials alone and in combination (dexamethasone) for multiple myeloma
Partnership status
Perifosine rights have been licensed to Keryx BioPharmaceuticals for North America. Æterna Zentaris has kept the rest of the world rights and is seeking partnerships for Asia

========================================

[Z]

http://www.aeternazentaris.com/en/page.php?p=56

Events and Webcast

May 6, 2009
Annual Shareholder Meeting
10:30 am (eastern time)
Centre Sheraton Montreal Hotel
1201 René-Lévesque Boulevard West, Montreal
Rooms 6 and 7

May 6, 2009
First quarter 2009 financial and operating results
3:30 pm (eastern time)
Conference call and Webcast
 
Ultima modifica:
Keryx Biopharmaceuticals - Financial and Strategic Analysis Review

Tue. May 05, 2009; Posted: 04:07 AM

Are you looking to increase your ETF knowledge?
May 04, 2009 (M2 PRESSWIRE via COMTEX) -- KERX | Quote | Chart | News | PowerRating -- -www.companiesandmarkets.com adds new report: Keryx Biopharmaceuticals - Financial and Strategic Analysis Review


Keryx Biopharmaceuticals - Financial and Strategic Analysis Review
Summary
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company engaged in the acquiring, developing and commercializing products for the treatment of Endocrine/Renal, Neurology and Oncology. The company product pipeline includes Sulonex, Zerenex, KRX-0401, KRX-0402, KRX-0404, KRX-0501, KRX-0601 and KRX-0701. The company principally operates in the US. The company is headquartered in New York, United States and employs 50 people.
This report presents an in-depth business, strategic and financial analysis of Keryx Biopharmaceuticals. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis and views on the company.
Scope
-The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
-The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
-The report contains critical company information - business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
-It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
-Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Reasons to buy
-A quick "one-stop-shop" to understand the company.
-Enhance business/sales activities by understanding customers' businesses better.
-Get detailed information and financial & strategic analysis on companies operating in your industry.
-Identify prospective partners and suppliers - with key data on their businesses and locations.
-Capitalize on competitors' weaknesses and target the market opportunities available to them.
-Compare your company's financial trends with those of your peers / competitors.
-Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
http://www.companiesandmarkets.com/link.asp?id=GPAPF2VHP73913
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 7813 784 393 Fax: +44 1536 790 144 e-mail: [email protected] WWW: http://www.companiesandmarkets.com/link.asp?id=GPAPF2VHP73913
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected].
For full details for KERX click here.
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 1 (members: 0, guests: 1)
Back
Alto